Influence of Aldehyde Dehydrogenase Inhibition on Stemness of Endometrial Cancer Stem Cells

Beatriz Serambeque,Catarina Mestre,Gabriela Correia-Barros,Ricardo Teixo,Carlos Miguel Marto,Ana Cristina Gonçalves,Francisco Caramelo,Isabel Silva,Artur Paiva,Hans C. Beck,Ana Sofia Carvalho,Maria Filomena Botelho,Maria João Carvalho,Rune Matthiesen,Mafalda Laranjo
DOI: https://doi.org/10.3390/cancers16112031
2024-05-28
Cancers
Abstract:Endometrial cancer is one of the most common gynaecological malignancies. Although often diagnosed at an early stage, there is a subset of patients with recurrent and metastatic disease for whom current treatments are not effective. Cancer stem cells (CSCs) play a pivotal role in triggering tumorigenesis, disease progression, recurrence, and metastasis, as high aldehyde dehydrogenase (ALDH) activity is associated with invasiveness and chemotherapy resistance. Therefore, this study aimed to evaluate the effects of ALDH inhibition in endometrial CSCs. ECC-1 and RL95-2 cells were submitted to a sphere-forming protocol to obtain endometrial CSCs. ALDH inhibition was evaluated through ALDH activity and expression, sphere-forming capacity, self-renewal, projection area, and CD133, CD44, CD24, and P53 expression. A mass spectrometry-based proteomic study was performed to determine the proteomic profile of endometrial cancer cells upon N,N-diethylaminobenzaldehyde (DEAB). DEAB reduced ALDH activity and expression, along with a significant decrease in sphere-forming capacity and projection area, with increased CD133 expression. Additionally, DEAB modulated P53 expression. Endometrial cancer cells display a distinct proteomic profile upon DEAB, sharing 75 up-regulated and 30 down-regulated proteins. In conclusion, DEAB inhibits ALDH activity and expression, influencing endometrial CSC phenotype. Furthermore, ALDH18A1, SdhA, and UBAP2L should be explored as novel molecular targets for endometrial cancer.
oncology
What problem does this paper attempt to address?
The paper aims to investigate the effects of aldehyde dehydrogenase (ALDH) inhibition on the characteristics of endometrial cancer stem cells (CSCs). Specifically, the researchers use N,N-diethylaminobenzaldehyde (DEAB) as an inhibitor to assess its impact on ALDH activity and expression, and further explore how this inhibition alters the behavior and phenotype of CSCs. The main objectives include: 1. **Evaluate the effects of ALDH inhibition**: By inhibiting ALDH enzyme activity, observe its impact on CSCs' self-renewal ability, sphere-forming capacity, and protein expression. 2. **Explore potential therapeutic targets**: Identify key proteins that may be affected by ALDH inhibition (such as ALDH18A1, SdhA, and UBAP2L), which could be new targets for future therapies. 3. **Validate the mechanism of ALDH inhibition**: Use techniques such as mass spectrometry to determine the proteomic impact of ALDH inhibition on endometrial cancer cells. Overall, the study aims to reveal the potential of ALDH inhibition in suppressing the growth and spread of endometrial cancer stem cells and provide a theoretical basis for developing new therapeutic strategies.